Portola Pharmaceuticals Inc (PTLA) : Randolph Co Inc added new position in Portola Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 125,450 shares of Portola Pharmaceuticals Inc which is valued at $2,674,594 , the company said in a statement filed on Oct 7, 2016 with the SEC.Portola Pharmaceuticals Inc makes up approximately 0.68% of Randolph Co Inc’s portfolio.
Other Hedge Funds, Including , Simplex Trading boosted its stake in PTLA in the latest quarter, The investment management firm added 6,190 additional shares and now holds a total of 9,316 shares of Portola Pharmaceuticals Inc which is valued at $198,617. Portola Pharmaceuticals Inc makes up approx 0.03% of Simplex Trading’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in PTLA in the latest quarter, The investment management firm added 2,192 additional shares and now holds a total of 4,146 shares of Portola Pharmaceuticals Inc which is valued at $94,860.
Portola Pharmaceuticals Inc closed down -0.36 points or -1.66% at $21.32 with 7,48,299 shares getting traded on Friday. Post opening the session at $22.45, the shares hit an intraday low of $21.06 and an intraday high of $22.45 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Portola Pharmaceuticals Inc reported $-1.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-1.17. The company had revenue of $4.20 million for the quarter, compared to analysts expectations of $2.11 million. The company’s revenue was up 75.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.12 EPS.
Many Wall Street Analysts have commented on Portola Pharmaceuticals Inc. Portola Pharmaceuticals Inc was Downgraded by Citigroup to ” Neutral” on Aug 19, 2016.
Portola Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs Betrixaban and Andexanet alfa address unmet medical needs in the area of thrombosis or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.